Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
XYLOCAINE vs ALPHACAINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lidocaine binds to and inhibits voltage-gated sodium channels in the neuronal membrane, stabilizing the membrane and preventing the initiation and conduction of nerve impulses, thereby producing local anesthesia.
Local anesthetic that reversibly blocks sodium ion channels in neuronal membranes, preventing the generation and propagation of action potentials.
Local anesthesia for infiltration, nerve block, epidural, spinal, and topical use,Treatment of acute ventricular arrhythmias (e.g., during cardiac surgery or myocardial infarction),Off-label: treatment of status epilepticus, neuropathic pain, and tinnitus
Local anesthesia by infiltration or nerve block,Spinal anesthesia,Epidural anesthesia
1-5 mg/kg (max 300 mg) local infiltration; epidural: 1-2% solution, 5-20 m L.
1–2% solution via local infiltration or nerve block, up to a maximum of 4.5 mg/kg (or 300 mg) without epinephrine; with epinephrine, maximum 7 mg/kg (or 500 mg).
Terminal elimination half-life is approximately 1.5 to 2 hours in adults, prolonged to 2-3 hours in patients with hepatic impairment, and may exceed 5 hours in neonates or patients with heart failure.
Terminal half-life 2.5-3.5 hours in adults; prolonged to 4-6 hours in hepatic impairment or elderly.
Primarily hepatic via CYP1A2 and CYP3A4 to active metabolites (monoethylglycinexylidide and glycinexylidide).
Hydrolyzed by plasma pseudocholinesterases to para-aminobenzoic acid and diethylaminoethanol.
Hepatic metabolism (primarily by CYP1A2 and CYP3A4) to metabolites, mainly monoethylglycinexylidide (MEGX) and glycinexylidide (GX); less than 10% excreted unchanged in urine. Renal excretion of metabolites: MEGX (70-80%) and GX (10-20%). Biliary/fecal elimination is minimal.
Primarily renal excretion of unchanged drug and metabolites (70-80%); minor biliary elimination (10-15%); fecal excretion <5%.
Approximately 65-70% bound to plasma proteins, primarily alpha-1-acid glycoprotein (AAG) and, to a lesser extent, albumin.
90-95% bound to alpha-1-acid glycoprotein and albumin.
Volume of distribution (Vd) is 0.8-1.3 L/kg. Higher Vd in neonates (up to 2.75 L/kg) indicates extensive tissue distribution.
Vd 0.8-1.2 L/kg; extensive tissue distribution (liver, lungs, brain).
Intravenous: 100%; Intramuscular: 70-90%; Epidural: near 100%; Topical: variable and low due to systemic absorption, typically <10%; Oral: less than 30% due to extensive first-pass metabolism.
Oral: 30-40% (first-pass metabolism); Intramuscular: 85-95%; Intravenous: 100%.
No adjustment required for GFR >30 m L/min; avoid in severe renal impairment (GFR <30 m L/min) due to risk of accumulation.
No specific dose adjustment required; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation. Monitor for CNS toxicity.
Child-Pugh A/B: reduce dose by 50%; Child-Pugh C: contraindicated.
Child-Pugh Class A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or use alternative agent.
1-2 mg/kg (max 4.5 mg/kg) local infiltration; adjust based on lean body weight.
Local infiltration: 0.5–2% solution, maximum 4.5 mg/kg (without epinephrine) or 7 mg/kg (with epinephrine). For nerve blocks: weight-based dosing, not to exceed adult maximum.
Reduce dose by 40-50% due to decreased clearance and increased sensitivity to CNS/cardiac effects.
Reduce total dose by 20–30% due to decreased clearance and increased sensitivity; monitor for prolonged effect and toxicity.
None.
Not available.
Risk of local anesthetic systemic toxicity (LAST) including CNS and cardiovascular effects, especially with inadvertent intravascular injection or high doses,Use with caution in patients with hepatic impairment, severe renal impairment, or hypovolemia,May cause methemoglobinemia, especially in infants,Monitor ECG when used intravenously for arrhythmias
Risk of systemic toxicity if absorbed into circulation,Hypersensitivity to ester-type anesthetics,Potential for methemoglobinemia with high doses,Use with caution in patients with impaired cardiac or hepatic function
Hypersensitivity to lidocaine or amide-type local anesthetics,Stokes-Adams syndrome or severe heart block (for IV antiarrhythmic use),Severe hypotension or cardiogenic shock,Do not use for spinal anesthesia if patient has bleeding disorders or infection at injection site
Hypersensitivity to ester-type anesthetics or para-aminobenzoic acid,Severe hypotension,Bleeding disorders (for spinal/epidural use),Infection at the injection site
No clinically significant food interactions reported.
No known food interactions. Avoid excessive grapefruit or grapefruit juice consumption due to potential CYP3A4 inhibition.
First trimester: No increased risk of major malformations observed in human studies. Second and third trimesters: Potential for fetal bradycardia and central nervous system depression with high maternal serum levels. Use only if clearly needed.
Alphacaine hydrochloride is a local anesthetic; limited human data but animal studies show no teratogenicity at clinically relevant doses. Fetal risk cannot be excluded; avoid in first trimester if possible.
Excreted into breast milk in low amounts (M/P ratio approximately 1.0). Considered compatible with breastfeeding; monitor for signs of local anesthetic toxicity in infant.
Excreted in breast milk in low amounts; M/P ratio not established. Consider risk-benefit; monitor infant for central nervous system depression.
No standard dose reduction required. Increased plasma volume and protein binding changes may reduce free drug concentration; however, toxicity may occur with standard doses due to altered clearance. Use lowest effective dose and consider patient weight.
No specific dose adjustments required; pharmacokinetics may be altered but clinical significance unclear.
Use minimum effective dose to avoid systemic toxicity; maximum dose without epinephrine is 4.5 mg/kg (not to exceed 300 mg), with epinephrine (1:200,000) is 7 mg/kg (not to exceed 500 mg). Rapid absorption from highly vascular areas (e.g., intercostal blocks) increases toxicity risk. Always aspirate before injection to prevent intravascular administration. Mixing with epinephrine prolongs duration and reduces peak plasma levels. For pediatric patients, calculate dose based on weight and use reduced concentrations (0.5-1%). In patients with hepatic impairment, reduce dose due to decreased metabolism. Concurrent use with CYP1A2 inhibitors (e.g., fluvoxamine) may increase lidocaine levels.
Alphacaine Hydrochloride is an amide-type local anesthetic similar to lidocaine. Onset of action is 2-5 minutes with duration of 30-120 minutes depending on concentration and use of epinephrine. It is hepatically metabolized (CYP3A4) and renally excreted. Dose adjustment required in hepatic impairment. Risk of methemoglobinemia, especially in infants and patients on sulfonamides. Do not exceed maximum doses: 4.5 mg/kg plain, 7 mg/kg with epinephrine.
Avoid driving or operating machinery until numbness and effects have completely worn off.,Do not eat or drink until sensation returns to prevent biting your tongue or cheek.,Report any signs of allergic reaction (rash, difficulty breathing, swelling) to your healthcare provider immediately.,If you experience dizziness, blurred vision, ringing in ears, or metallic taste, seek emergency care.,Inform your doctor about all medications you take, especially heart medications, anticoagulants, or other local anesthetics.,Numbness and lack of sensation are normal during the procedure; do not scratch or rub the numbed area.
Avoid alcohol consumption for 24 hours after procedure.,Inform your doctor if you have liver disease, heart block, or history of methemoglobinemia.,Do not drive or operate machinery until effects wear off.,Report numbness, tingling, or twitching immediately.,For dental procedures: avoid eating until numbness resolves to prevent injury.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about XYLOCAINE vs ALPHACAINE HYDROCHLORIDE, answered by our medical review team.
XYLOCAINE is a Local Anesthetic that works by Lidocaine binds to and inhibits voltage-gated sodium channels in the neuronal membrane, stabilizing the membrane and preventing the initiation and conduction of nerve impulses, thereby producing local anesthesia.. ALPHACAINE HYDROCHLORIDE is a Local Anesthetic that works by Local anesthetic that reversibly blocks sodium ion channels in neuronal membranes, preventing the generation and propagation of action potentials.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between XYLOCAINE and ALPHACAINE HYDROCHLORIDE depend on the specific clinical indication. These are both Local Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of XYLOCAINE is: 1-5 mg/kg (max 300 mg) local infiltration; epidural: 1-2% solution, 5-20 m L.. The standard adult dose of ALPHACAINE HYDROCHLORIDE is: 1–2% solution via local infiltration or nerve block, up to a maximum of 4.5 mg/kg (or 300 mg) without epinephrine; with epinephrine, maximum 7 mg/kg (or 500 mg).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between XYLOCAINE and ALPHACAINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. XYLOCAINE is classified as Category C. First trimester: No increased risk of major malformations observed in human studies. Second and third trimesters: Potential for fetal bradycardia and central nervous system depress. ALPHACAINE HYDROCHLORIDE is classified as Category C. Alphacaine hydrochloride is a local anesthetic; limited human data but animal studies show no teratogenicity at clinically relevant doses. Fetal risk cannot be excluded; avoid in f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.